Particle.news
Download on the App Store
3 ARTICLES
·
1h ago

Genmab Makes $8 Billion Bid for Merus to Build Utrecht Biotech Hub

Genmab points to Merus’s petosemtamab as the catalyst for creating a larger research base in Utrecht.

Image
Image
Image

Overview

  • Genmab announced a formal takeover bid on Monday for Dutch biotech Merus valued at about $8 billion.
  • CEO Jan van de Winkel described petosemtamab data as “spectacular” and said the move would be very good for the Netherlands.
  • The company outlines plans for an R&D conglomerate in Utrecht and signals expansions at select locations.
  • Genmab intends to retain ownership of new medicines from the combined group and to commercialize them directly.
  • Merus, founded in 2003 with a Cambridge, U.S., site and roughly 260 employees, saw its shares surge after promising May results for investigational petosemtamab, with a possible 2027 launch characterized as hopeful.